Acalabrutinib

About

Therapy type: Targeted therapy

Therapy strategy: BTK inhibition

Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) TP53 somatic variants Chronic Lymphocytic Leukemia Acalabrutinib
Sensitivity (+) TP53 deletion Chronic Lymphocytic Leukemia Acalabrutinib
Sensitivity (+) 17p deletion Chronic Lymphocytic Leukemia Acalabrutinib